Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
The need for more Latinx participants in Alzheimer's trials is urgent.
2.
Parkinson patient's gait is restored by a spinal cord stimulator.
3.
Taking vitamin D daily decreased cancer mortality, according to a study.
4.
Obesity-associated cancers may be on the rise in Puerto Rico
5.
Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control
1.
Colon Cancer Staging: What You Need to Know
2.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
3.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
4.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
5.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge